These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 27370604)

  • 1. Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.
    Zook P; Pathak HB; Belinsky MG; Gersz L; Devarajan K; Zhou Y; Godwin AK; von Mehren M; Rink L
    Clin Cancer Res; 2017 Jan; 23(1):171-180. PubMed ID: 27370604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor.
    Kim TS; Cavnar MJ; Cohen NA; Sorenson EC; Greer JB; Seifert AM; Crawley MH; Green BL; Popow R; Pillarsetty N; Veach DR; Ku AT; Rossi F; Besmer P; Antonescu CR; Zeng S; Dematteo RP
    Clin Cancer Res; 2014 May; 20(9):2350-62. PubMed ID: 24583793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.
    Gebreyohannes YK; Schöffski P; Van Looy T; Wellens J; Vreys L; Cornillie J; Vanleeuw U; Aftab DT; Debiec-Rychter M; Sciot R; Wozniak A
    Mol Cancer Ther; 2016 Dec; 15(12):2845-2852. PubMed ID: 27777285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor.
    Vitiello GA; Medina BD; Zeng S; Bowler TG; Zhang JQ; Loo JK; Param NJ; Liu M; Moral AJ; Zhao JN; Rossi F; Antonescu CR; Balachandran VP; Cross JR; DeMatteo RP
    Clin Cancer Res; 2018 Feb; 24(4):972-984. PubMed ID: 29246941
    [No Abstract]   [Full Text] [Related]  

  • 5. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
    Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB
    Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.
    Garner AP; Gozgit JM; Anjum R; Vodala S; Schrock A; Zhou T; Serrano C; Eilers G; Zhu M; Ketzer J; Wardwell S; Ning Y; Song Y; Kohlmann A; Wang F; Clackson T; Heinrich MC; Fletcher JA; Bauer S; Rivera VM
    Clin Cancer Res; 2014 Nov; 20(22):5745-5755. PubMed ID: 25239608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors.
    Li F; Huynh H; Li X; Ruddy DA; Wang Y; Ong R; Chow P; Qiu S; Tam A; Rakiec DP; Schlegel R; Monahan JE; Huang A
    Cancer Discov; 2015 Apr; 5(4):438-51. PubMed ID: 25673643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.
    Smyth T; Van Looy T; Curry JE; Rodriguez-Lopez AM; Wozniak A; Zhu M; Donsky R; Morgan JG; Mayeda M; Fletcher JA; Schöffski P; Lyons J; Thompson NT; Wallis NG
    Mol Cancer Ther; 2012 Aug; 11(8):1799-808. PubMed ID: 22714264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.
    Rausch JL; Boichuk S; Ali AA; Patil SS; Liu L; Lee DM; Brown MF; Makielski KR; Liu Y; Taguchi T; Kuan SF; Duensing A
    Oncotarget; 2017 Jan; 8(3):4471-4483. PubMed ID: 27965460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
    Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
    Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
    Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
    Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coordinated targeting of CK2 and KIT in gastrointestinal stromal tumours.
    Huang M; Yang W; Zhu J; Mariño-Enríquez A; Zhu C; Chen J; Wu Y; Quan Y; Qiu H; Li X; Chai L; Fletcher JA; Ou WB
    Br J Cancer; 2020 Feb; 122(3):372-381. PubMed ID: 31776458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
    Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors.
    Bardsley MR; Horváth VJ; Asuzu DT; Lorincz A; Redelman D; Hayashi Y; Popko LN; Young DL; Lomberk GA; Urrutia RA; Farrugia G; Rubin BP; Ordog T
    Gastroenterology; 2010 Sep; 139(3):942-52. PubMed ID: 20621681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.
    Floris G; Wozniak A; Sciot R; Li H; Friedman L; Van Looy T; Wellens J; Vermaelen P; Deroose CM; Fletcher JA; Debiec-Rychter M; Schöffski P
    Clin Cancer Res; 2013 Feb; 19(3):620-30. PubMed ID: 23231951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition.
    Hemming ML; Lawlor MA; Andersen JL; Hagan T; Chipashvili O; Scott TG; Raut CP; Sicinska E; Armstrong SA; Demetri GD; Bradner JE
    Cancer Res; 2019 Mar; 79(5):994-1009. PubMed ID: 30630822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated Screens Identify CDK1 as a Therapeutic Target in Advanced Gastrointestinal Stromal Tumors.
    Lu X; Pang Y; Cao H; Liu X; Tu L; Shen Y; Jia X; Lee JC; Wang Y
    Cancer Res; 2021 May; 81(9):2481-2494. PubMed ID: 33727226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.
    Mahadevan D; Cooke L; Riley C; Swart R; Simons B; Della Croce K; Wisner L; Iorio M; Shakalya K; Garewal H; Nagle R; Bearss D
    Oncogene; 2007 Jun; 26(27):3909-19. PubMed ID: 17325667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KIT
    Banerjee S; Yoon H; Ting S; Tang CM; Yebra M; Wenzel AT; Yeerna H; Mesirov JP; Wechsler-Reya RJ; Tamayo P; Sicklick JK
    Mol Cancer Ther; 2021 Oct; 20(10):2035-2048. PubMed ID: 34376580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor.
    García-Valverde A; Rosell J; Serna G; Valverde C; Carles J; Nuciforo P; Fletcher JA; Arribas J; Politz O; Serrano C
    Mol Cancer Ther; 2020 Jun; 19(6):1289-1297. PubMed ID: 32371592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.